Introduction: According to the current American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, patients with normal cytology results may be referred for colposcopy according to their high-risk human papillomavirus (hrHPV) test results. A higher positive predictive value (PPV) of hrHPV has significance for preventing unnecessary colposcopic examinations. Several studies have compared the performance of the Aptima assay and the Cobas 4800 platform among patients who had minor cytologic abnormalities. However, in our English literature search, we found no other study that had been conducted to compare these two methods in patients with normal cytology. We thus aimed to compare the PPV of the Aptima assay and the Cobas 4800 platform among women with normal cytology. Methods: Between September 2017 and October 2022, we retrospectively identified 2,919 patients who had normal cytology and hrHPV positivity and had been referred for a colposcopy. Among them, 882 agreed to undergo a colposcopy; on examination, 134 had target lesions revealed and underwent a colposcopic punch biopsy. Results: Among the patients who underwent a colposcopic punch biopsy, 49 (38.9%) were tested with Aptima, and 77 (61.1%) were tested with Cobas. In the Aptima group, 29 (59.2%) patients showed benign histology, 2 (4.1%) patients had low-grade squamous intraepithelial lesions (LSILs), and 18 (36.7%) patients had ≥high-grade squamous intraepithelial lesions (HSILs) biopsy results. The false-positivity rate and PPV of Aptima were 63.3% (31/49) and 36.7% (95% confidence interval [CI]: 0.232–0.502), respectively, for a histopathologic diagnosis of ≥HSIL. In the Cobas group, 48 (62.3%) biopsies were benign, 11 (14.3%) reported an LSIL, and 18 (23.4%) biopsies were ≥HSIL. The false-positivity rate and PPV of Cobas were 76.6% (59/77) and 23.4% (95% CI: 0.139–0.328), respectively, concerning a ≥HSIL tissue diagnosis. The false-positivity rate of Aptima HPV 16 positivity was 40% (4/10). The false-positivity rate of Cobas HPV 16 positivity was 61.1% (11/18). The PPVs of HPV 16 positivity for Aptima and Cobas were 60% (95% CI: 0.296–0.903) and 38.9% (95% CI: 0.163–0.614), respectively, concerning ≥HSIL tissue diagnosis. Conclusion: We recommend analyzing the performances of hrHPV platforms in future, larger studies in patients with normal cytology rather than only in cases with abnormal cytology.

1.
Sung
H
,
Ferlay
J
,
Siegel
RL
,
Laversanne
M
,
Soerjomataram
I
,
Jemal
A
.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2021 May
71
3
209
49
.
2.
Lin
S
,
Gao
K
,
Gu
S
,
You
L
,
Qian
S
,
Tang
M
.
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years
.
Cancer
.
2021 Nov
127
21
4030
9
.
3.
Turkiye_Kanser_Istatistikleri_2017 (Internet)
. Available from: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Turkiye_Kanser_Istatistikleri_2017.pdf.
4.
Cohen
PA
,
Jhingran
A
,
Oaknin
A
,
Denny
L
.
Cervical cancer
.
Lancet
.
2019
;
393
(
10167
):
169
82
.
5.
Perkins
RB
,
Guido
RS
,
Castle
PE
,
Chelmow
D
,
Einstein
MH
,
Garcia
F
.
2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors
.
J Low Genit Tract Dis
.
2020 Apr
24
2
102
31
.
6.
Salazar
KL
,
Duhon
DJ
,
Olsen
R
,
Thrall
M
.
A review of the FDA-approved molecular testing platforms for human papillomavirus
.
J Am Soc Cytopathol
.
2019 Sep–Oct
8
5
284
92
.
7.
ThinPrep® 2000 System Operator’s Manual [Internet]
. Available from: http://hologic.com/.
8.
Heideman
DAM
,
Hesselink
AT
,
Berkhof
J
,
van Kemenade
F
,
Melchers
WJG
,
Daalmeijer
NF
.
Clinical validation of the cobas 4,800 HPV test for cervical screening purposes
.
J Clin Microbiol
.
2011 Nov
49
11
3983
5
.
9.
Cobas® 4800 HPV Test [Internet]
. Available from: https://diagnostics.roche.com/.
10.
Lee
H
,
Lee
KJ
,
Jung
CK
,
Hong
JH
,
Lee
YS
,
Choi
YJ
.
Expression of HPV L1 capsid protein in cervical specimens with HPV infection
.
Diagn Cytopathol
.
2008 Dec
36
12
864
7
.
11.
Liu
TY
,
Xie
R
,
Luo
L
,
Reilly
KH
,
He
C
,
Lin
YZ
.
Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples
.
J Virol Methods
.
2014 Feb
196
120
5
.
12.
Haedicke
J
,
Iftner
T
.
A review of the clinical performance of the Aptima HPV assay
.
J Clin Virol
.
2016 Mar
76
Suppl 1
40
8
.
13.
Giorgi Rossi
P
,
Carozzi
FM
,
Ronco
G
,
Allia
E
,
Bisanzi
S
,
Gillio-Tos
A
.
P16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women
.
J Natl Cancer Inst
.
2021 Mar
113
3
292
300
.
14.
Castle
PE
,
Eaton
B
,
Reid
J
,
Getman
D
,
Dockter
J
.
Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology
.
J Clin Microbiol
.
2015 Apr
53
4
1277
81
.
15.
Wang
T
,
Pradhan
D
,
Zhang
H
,
Matsko
J
,
Zhao
C
.
Clinical performance of the aptima HPV assay in 4,196 women with positive high-risk HPV and ASC-US cytology: a large women hospital experience
.
Diagn Cytopathol
.
2021 Jan
49
1
5
10
.
16.
Tewari
P
,
White
C
,
Kelly
L
,
Pilkington
L
,
Keegan
H
,
D’Arcy
T
.
Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities
.
Diagn Cytopathol
.
2018 Dec
46
12
987
92
.
17.
Ge
Y
,
Christensen
P
,
Luna
E
,
Armylagos
D
,
Schwartz
MR
,
Mody
DR
.
Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer
.
Cancer Cytopathol
.
2017 Aug
125
8
652
7
.
18.
Ge
Y
,
Christensen
P
,
Luna
E
,
Armylagos
D
,
Xu
J
,
Schwartz
MR
.
Aptima human papillomavirus E6/E7 mRNA test results strongly associated with risk for high-grade cervical lesions in follow-up biopsies
.
J Low Genit Tract Dis
.
2018 Jul
22
3
195
200
.
19.
Goodman
S
,
Mody
RR
,
Coffey
D
,
Gorman
BK
,
Luna
E
,
Armylagos
D
.
Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: contributing factors and role of human papillomavirus genotyping
.
Diagn Cytopathol
.
2018 Mar
46
3
239
43
.
You do not currently have access to this content.